Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Novo Nordisk ( (NVO) ) just unveiled an announcement.
Novo Nordisk said on 22 May 2026 that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending EU marketing authorisation for Wegovy pill, a once-daily 25 mg oral semaglutide, as the first oral GLP-1 therapy for weight management. The decision, based on the OASIS and SELECT programmes, positions the pill as a best-in-class oral obesity treatment with mean weight loss of 16.6% in OASIS 4, efficacy similar to injectable Wegovy, and label data showing reduced risk of major adverse cardiovascular events.
The oral Wegovy pill also carries no drug–drug restrictions in its label and reaffirmed semaglutide’s established safety and tolerability profile, supported by over 50 million patient-years of real-world data. Novo Nordisk plans to launch the product in select markets outside the U.S. in the second half of 2026, a move that could materially expand its obesity franchise, deepen its cardiometabolic footprint in Europe, and capitalise on strong early U.S. demand, where more than 1 million patients initiated Wegovy pill within four months of launch.
The most recent analyst rating on (NVO) stock is a Hold with a $45.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
The score is driven primarily by strong underlying profitability and multi-year growth (financial performance), supported by very attractive valuation (low P/E and high dividend). Offsetting these positives are weaker recent free-cash-flow conversion and higher leverage, plus a cautious 2026 outlook calling for declining sales and operating profit; technically, momentum is positive but appears overbought and still below the 200-day trend.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, with a core focus on defeating serious chronic diseases rooted in its diabetes heritage. The group develops and markets therapies such as semaglutide-based treatments for obesity and cardiometabolic conditions, employs about 67,900 people in 80 countries, and sells its products in around 170 countries, with listings in Copenhagen and New York.
Average Trading Volume: 20,260,487
Technical Sentiment Signal: Sell
Current Market Cap: $199.1B
Find detailed analytics on NVO stock on TipRanks’ Stock Analysis page.